We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Synthorx Inc | NASDAQ:THOR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 67.99 | 67.00 | 67.99 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
SYNTHORX, INC.
(Name of Subject Company)
SYNTHORX, INC.
(Name of Person Filing Statement)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
87167A103
(CUSIP Number of Class of Securities)
Laura Shawver, Ph.D.
President and Chief Executive Officer
Synthorx, Inc.
11099 N. Torrey Pines Road, Suite 190
San Diego, California 92037
(858) 750-4700
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
Barbara Borden, Esq.
Rama Padmanabhan, Esq.
Kenneth J. Rollins, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, CA 92121
(858) 550-6000
☒ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
On December 8, 2019, Synthorx, Inc. (Synthorx) and Sanofi issued a joint press release announcing the execution of an Agreement and Plan of Merger (the Merger Agreement). Pursuant to the Merger Agreement, Thunder Acquisition Corp., a wholly owned subsidiary of Sanofi (Purchaser), will commence a cash tender offer (the Offer) to purchase all of the issued and outstanding shares of Synthorx common stock, for $68.00 per share in cash. If successful, the Offer will be followed by a merger of Purchaser with and into Synthorx (the Merger).
This Schedule 14D-9 filing consists of the following documents relating to the proposed Offer and Merger:
(i) | Synthorx employee FAQs, first made available on December 9, 2019. | |
(ii) | Letter to Synthorx employees from Sanofi, first made available on December 9, 2019. |
1 Year Synthorx Chart |
1 Month Synthorx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions